Hua Xu
Director, Head of Chemical Biology and Proteomics AstraZeneca
Hua Xu is Director and Head of Chemical Biology and Proteomics at AstraZeneca, where he leads strategy and innovation in mechanistic biology, chemoproteomics, and targeted proteomic technologies. With extensive experience building capabilities for emerging modalities, including covalent inhibitors, PROTACs, molecular glues, and antibody-based degraders, Hua has advanced discovery programmes by integrating biochemical, cellular, and mass-spectrometry approaches. He has overseen cross-functional teams, driven proteomics-enabled hit identification, and strengthened translational decision-making across therapeutic areas. At the Summit, Hua will discuss how chemoproteomics and activity-based protein profiling can map target engagement in complex systems to guide compound selection and development.
Seminars
- Explore strategies to measure binding and functional engagement in cellular or complex protein environments
- Learn how chemoproteomics complements biophysical screening to validate hits and guide compound selection
- Discuss how these approaches inform later-stage translational decisions
